National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis.
atopic dermatitis
early diagnosis
information campaign
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Sep 2022
02 Sep 2022
Historique:
received:
18
07
2022
revised:
21
08
2022
accepted:
27
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Atopic dermatitis (AD) is a common inflammatory skin disease often associated with a significant impairment in the quality of life of affected patients. The Italian Society of Dermatology and Venereology (SIDeMaST) planned a national information campaign, providing direct access to 27 dermatologic centers dedicated to the management of AD. The aim of this study aimed was to outline critical aspects related to AD in the general population. Overall, 643 adult subjects were included in this study, and in 44.2% (284/643) of cases, a diagnosis of AD was confirmed, whereas about 55% of subjects were affected by other pruritic cutaneous diseases. Higher intensity of pruritus and sleep disturbance, as well as an increased interference in sport, work, and social confidence was reported in the AD group compared to the non-AD group. In the AD subgroup, the mean duration of disease was of 15.3 years, with a mean eczema area and severity index (EASI) score of 11.2, and investigator global assessment (IGA) score of 1.9 and an itch numeric rating scale (NRS) of 6.9. Almost 32% of patients were untreated, either with topical or systemic agents, whereas 44.3% used routine topical compounds (topical corticosteroids and calcineurin inhibitors), and only 7.0% of patients were systemically treated. Only 2.8% of patients reported complete satisfaction with the treatment received for AD to date. This study reveals a profound unmet need in AD, showing a poorly managed and undertreated patient population despite a high reported burden of disease. This suggests the usefulness of information campaigns with the goal of improving patient awareness regarding AD and facilitating early diagnosis and access to dedicated healthcare institutions.
Identifiants
pubmed: 36079131
pii: jcm11175204
doi: 10.3390/jcm11175204
pmc: PMC9457191
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest related to this study.
Références
Acta Derm Venereol. 2019 Mar 1;99(3):263-267
pubmed: 30521060
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):850-878
pubmed: 29878606
Eur J Dermatol. 2022 Feb 1;32(1):34-48
pubmed: 34911672
Biomed Res Int. 2021 May 6;2021:6672506
pubmed: 34041301
N Engl J Med. 2014 Jul 10;371(2):130-9
pubmed: 25006719
J Investig Allergol Clin Immunol. 2017;27(2):78-88
pubmed: 28071589
J Allergy Clin Immunol. 2018 Oct;142(4):1033-1040
pubmed: 30144472
J Dermatolog Treat. 2022 Aug;33(5):2459-2465
pubmed: 34445932
Mediators Inflamm. 2003 Apr;12(2):123-5
pubmed: 12775363
J Eur Acad Dermatol Venereol. 2011 Jan;25(1):12-8
pubmed: 20569298
Clin Exp Dermatol. 2021 Jan;46(1):157-161
pubmed: 32803784
Ann Allergy Asthma Immunol. 2019 Aug;123(2):144-151
pubmed: 31034875
Int J Dermatol. 2020 Apr;59(4):e75-e91
pubmed: 31930494
Indian Dermatol Online J. 2013 Jul;4(3):167-71
pubmed: 23984225
Ital J Dermatol Venerol. 2021 Apr;156(2):184-197
pubmed: 32438781
Am J Clin Dermatol. 2018 Feb;19(1):15-22
pubmed: 28624959
J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682
pubmed: 29676534
Drug Des Devel Ther. 2017 May 15;11:1473-1480
pubmed: 28553077
Chin Med J (Engl). 2016 Apr 5;129(7):757-62
pubmed: 26996468
Nat Rev Drug Discov. 2022 Jan;21(1):21-40
pubmed: 34417579
Br J Dermatol. 2016 Apr;174(4):853-61
pubmed: 26686685
Mediators Inflamm. 2006;2006(4):73098
pubmed: 17047294
Acta Derm Venereol. 2020 Jun 9;100(12):adv00161
pubmed: 32412644
Arch Pediatr Adolesc Med. 1999 Mar;153(3):249-53
pubmed: 10086401
Lancet. 2017 Jun 10;389(10086):2287-2303
pubmed: 28478972
J Am Acad Dermatol. 2014 Feb;70(2):338-51
pubmed: 24290431
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1405-1411
pubmed: 30767284
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242